<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="italic;} Int J Infect DisInt. J. Infect. DisInternational Journal of" exact="Infectious" post="Diseases1201-97121878-3511Published by Elsevier Ltd on behalf of International Society"/>
 <result pre="Diseases1201-97121878-3511Published by Elsevier Ltd on behalf of International Society for" exact="Infectious" post="Diseases. pmcid: 7497732S1201-9712(20)30753-0 doi: 10.1016/j.ijid.2020.09.037 : Article The importance"/>
 <result pre="the correct interpretation of the hospital fatality rate in COVID-19" exact="disease" post="dâ€™Arminio MonforteAntonellaaâ�ŽTavelliAlessandroaBaiFrancescaaTomasoniDanieleaFalcinellaCamillaaCastoldiRobertoaBarbanottiDilettaaMulÃ¨GiovanniaAllegriniMarinaaTesoroDanieleaTagliaferriGianmarcoaMondatoreDeboraaAugelloMatteoaConaAndreaaAnconaGiuseppeaGazzolaLidiaaIannottiNathalieaTincatiCamillaaViganÃ²OttaviaaDe BonaAnnaaBiniTeresaaCozzi-LepriAlessandrobMarchettiGiuliaa[a], [b], â�ŽCorresponding author at: Institute of"/>
 <result pre="disease dâ€™Arminio MonforteAntonellaaâ�ŽTavelliAlessandroaBaiFrancescaaTomasoniDanieleaFalcinellaCamillaaCastoldiRobertoaBarbanottiDilettaaMulÃ¨GiovanniaAllegriniMarinaaTesoroDanieleaTagliaferriGianmarcoaMondatoreDeboraaAugelloMatteoaConaAndreaaAnconaGiuseppeaGazzolaLidiaaIannottiNathalieaTincatiCamillaaViganÃ²OttaviaaDe BonaAnnaaBiniTeresaaCozzi-LepriAlessandrobMarchettiGiuliaa[a], [b], â�ŽCorresponding author at: Institute of" exact="Infectious" post="and Tropical Diseases, Department of Health Sciences, ASST Santi"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Methods Prospective observational cohort study on patients hospitalised with COVID-19" exact="disease" post="in February-24th/May-17th 2020 in Milan, Italy. Uni-multivariable Cox regression"/>
 <result pre="performed. Deathâ€™s percentage by two-weeksâ€™ intervals according to age and" exact="disease" post="severity was analysed. Results A total of 174/539 (32.3%)"/>
 <result pre="according to age and disease severity was analysed. Results A" exact="total" post="of 174/539 (32.3%) patients died in hospital over 8228"/>
 <result pre="was 29.5% (95%CI: 25.5â€&quot;34.0). Older age, burden of comorbidities, COVID-19" exact="disease" post="severity, inflammatory markers at admission were independent predictors of"/>
 <result pre="overload of hospitals and intensive care units (ICU). In a" exact="short" post="time span, all the hospitals were overwhelmed by dozens"/>
 <result pre="the hospitals were overwhelmed by dozens of citizens suffering from" exact="acute" post="respiratory distress and the different departments were rapidly shifted"/>
 <result pre="hospitals were overwhelmed by dozens of citizens suffering from acute" exact="respiratory" post="distress and the different departments were rapidly shifted to"/>
 <result pre="should be taken in consideration, that include the reference population," exact="disease" post="severity, but also presence of comorbidities and the availability"/>
 <result pre="in-hospital death in a cohort of hospitalised patients with COVID-19" exact="disease" post="in a single hospital in Milan. Methods Setting San"/>
 <result pre="University hospital with 426 beds of all specialities, including ICU," exact="infectious diseases," post="and pneumology. Since end of February, increasing number of"/>
 <result pre="1). Doctors and nurses converged in multidisciplinary teams leaded by" exact="infectious diseases," post="pneumology and intensive care physicians. Design Prospective observational cohort"/>
 <result pre="patients admitted to the San Paolo Hospital in Milan with" exact="symptomatic" post="SARS CoV-2 infection between February 24 and May 17,"/>
 <result pre="the San Paolo Hospital in Milan with symptomatic SARS CoV-2" exact="infection" post="between February 24 and May 17, 2020. Subjects and"/>
 <result pre="2020. Subjects and methods Inclusion criteria were: -confirmed diagnosis of" exact="symptomatic" post="SARS CoV-2 infection by RT-PCR on naso-pharyngeal or oro-pharyngeal"/>
 <result pre="methods Inclusion criteria were: -confirmed diagnosis of symptomatic SARS CoV-2" exact="infection" post="by RT-PCR on naso-pharyngeal or oro-pharyngeal or broncho-alveolar swab"/>
 <result pre="age-unadjusted Charlson comorbidity index (Charlson et al., 1987); symptoms; obesity;" exact="respiratory" post="rate (RR), oxygen saturation percent (SO2); computerised tomography (CT);"/>
 <result pre="scan was evaluated as: no pathological findings; interstitial pneumonia; consolidation;" exact="pleural" post="effusion. Mono- or bilateral extension was collected. Disease severity"/>
 <result pre="no pathological findings; interstitial pneumonia; consolidation; pleural effusion. Mono- or" exact="bilateral" post="extension was collected. Disease severity at admission was classified"/>
 <result pre="pneumonia; consolidation; pleural effusion. Mono- or bilateral extension was collected." exact="Disease" post="severity at admission was classified as mild (no pneumonia);"/>
 <result pre="(RR &amp;lt; 24/min; SO2 &amp;lt; 92%; PaO2/FiO2 100â€&quot;300 mmHg); critical" exact="disease" post="(PaO2/FiO2 &amp;lt; 100 mmHg). The highest intensity of ventilation"/>
 <result pre="non-invasive or invasive ventilation. Criteria for invasive mechanical ventilation were" exact="acute" post="respiratory distress (PaO2/FiO2 &amp;lt;100 mmHg) and no major conditions"/>
 <result pre="or invasive ventilation. Criteria for invasive mechanical ventilation were acute" exact="respiratory" post="distress (PaO2/FiO2 &amp;lt;100 mmHg) and no major conditions determining"/>
 <result pre="respiratory distress (PaO2/FiO2 &amp;lt;100 mmHg) and no major conditions determining" exact="short" post="life expectancy. Antivirals; low molecular weight heparin; hydroxychloroquine Â±"/>
 <result pre="corticosteroids were collected and grouped according to the combinations used." exact="Primary" post="end-point was time to in-hospital death. Factors associated were"/>
 <result pre="role of comorbidities. We also evaluated the dynamics of the" exact="disease" post="in terms of severity at presentation, age of patients,"/>
 <result pre="of other variables at admission including demographics, period of admission," exact="disease" post="severity; CRP, d-dimer; use of anti-Covid-19 drug combinations. A"/>
 <result pre="105 (15.3%) did not require hospitalisation and were excluded. A" exact="total" post="of 539 (78.5%) patients were hospitalised for SARS CoV-2"/>
 <result pre="total of 539 (78.5%) patients were hospitalised for SARS CoV-2" exact="symptomatic" post="infection. In a median follow-up of 71 days (IQR:"/>
 <result pre="COVID-19 disease, 56 (10.4%) were resident in long-term facilities. A" exact="total" post="of 77 (14.3%) were obese (e.g. BMI &amp;gt; 30"/>
 <result pre="suffered from hypertension, 95 (17.6%) from diabetes, 147 (27.3%) from" exact="cardiovascular disease." post="Median days from onset of symptoms to admission were"/>
 <result pre="from onset of symptoms to admission were 6 (IQR: 3â€&quot;10)." exact="Fever" post="was present in 86% of cases, dyspnoea in 55.7%"/>
 <result pre="no radiological signs of pneumonia; in 242 patients (44.9%) the" exact="disease" post="was moderate; in 244 patients (45.3%) the disease was"/>
 <result pre="(44.9%) the disease was moderate; in 244 patients (45.3%) the" exact="disease" post="was severe and in 18 (3.6%) critical with high-grade"/>
 <result pre="disease was severe and in 18 (3.6%) critical with high-grade" exact="respiratory" post="distress. In half of the patients (262, 48.7%) the"/>
 <result pre="Demographic and clinical characteristics of 539 patients hospitalised for COVID-19" exact="disease" post="according to in-hospital death. Table 1 In-hospital survival In-hospital"/>
 <result pre="according to in-hospital death. Table 1 In-hospital survival In-hospital death" exact="Total" post="p N = 367 (67.7) N = 174 (32.3)"/>
 <result pre="24 (6.6) 33 (19.0) 57 (10.6) Comorbidities, N (%) Â" exact="Hypertension" post="145 (39.7) 105 (60.3) 250 (46.4) &amp;lt;0.001 Â Diabetes"/>
 <result pre="Â Hypertension 145 (39.7) 105 (60.3) 250 (46.4) &amp;lt;0.001 Â" exact="Diabetes" post="49 (13.4) 46 (26.4) 95 (17.6) &amp;lt;0.001 Â Cardiovascular"/>
 <result pre="Cardiovascular diseasesa 72 (19.7) 75 (43.1) 147 (27.3) &amp;lt;0.001 Â" exact="Cerebrovascular" post="diseasesb 21 (5.7) 24 (13.8) 45 (8.3) 0.002 Â"/>
 <result pre="Cerebrovascular diseasesb 21 (5.7) 24 (13.8) 45 (8.3) 0.002 Â" exact="Chronic" post="obstructive pulmonary disease/asthma 43 (11.8) 31 (17.8) 74 (13.7)"/>
 <result pre="21 (5.7) 24 (13.8) 45 (8.3) 0.002 Â Chronic obstructive" exact="pulmonary" post="disease/asthma 43 (11.8) 31 (17.8) 74 (13.7) 0.057 Â"/>
 <result pre="pulmonary disease/asthma 43 (11.8) 31 (17.8) 74 (13.7) 0.057 Â" exact="Chronic" post="liver diseases/cirrhosis 12 (3.3) 7 (4.0) 19 (3.5) 0.665"/>
 <result pre="haematological malignancy 17 (4.7) 21 (12.1) 38 (7.0) 0.002 Â" exact="Chronic" post="kidney disease 17 (4.7) 24 (138) 41 (7.6) &amp;lt;0.001"/>
 <result pre="malignancy 17 (4.7) 21 (12.1) 38 (7.0) 0.002 Â Chronic" exact="kidney disease" post="17 (4.7) 24 (138) 41 (7.6) &amp;lt;0.001 Â HIV"/>
 <result pre="17 (4.7) 21 (12.1) 38 (7.0) 0.002 Â Chronic kidney" exact="disease" post="17 (4.7) 24 (138) 41 (7.6) &amp;lt;0.001 Â HIV"/>
 <result pre="(3â€&quot;10) 0.001 Signs and symptoms at admission, N (%) Â" exact="Fever" post="312 (85.5) 153 (87.9) 465 (86.3) 0.439 Â Dyspnea"/>
 <result pre="Headache 9 (2.5) 2 (1.2) 11 (2.0) 0.312 Â Other" exact="respiratory" post="symptoms 18 (4.9) 5 (2.9) 23 (4.3) 0.269 Â"/>
 <result pre="18 (4.9) 5 (2.9) 23 (4.3) 0.269 Â Other non" exact="respiratory" post="symptoms 26 (7.1) 32 (18.4) 58 (10.8) &amp;lt;0.001 COVID-19"/>
 <result pre="(6.5) Â Moderate 197 (54.0) 45 (25.9) 242 (44.9) Â" exact="Severe" post="137 (37.5) 107 (61.5) 244 (45.3) Â Critical 3"/>
 <result pre="18 (3.6) Â Missing 25 (6.8) 20 (11.5) 45 (8.3)" exact="Respiratory" post="rate at admission, breaths/min, median (IQR) 22 (18â€&quot;28) 28"/>
 <result pre="CT scan findings, N (%) 0.059 Â No signs of" exact="pneumonia" post="33 (9.0) 10 (5.7) 43 (7.9) Â Pulmanary infiltrates/ground"/>
 <result pre="infiltrates/ground glass opacities 123 (33.7) 60 (34.5) 183 (33.9) Â" exact="Bilateral" post="involvement 292 (87.9) 137 (83.5) 429 (86.5) 0.372 Â"/>
 <result pre="Bilateral involvement 292 (87.9) 137 (83.5) 429 (86.5) 0.372 Â" exact="Pleural" post="effusion 42 (11.5) 27 (15.5) 69 (12.8) 0.193 Hemoglobin,"/>
 <result pre="(IQR) 13 (7â€&quot;25) 6 (5â€&quot;12) 10 (6â€&quot;21) &amp;lt;0.001 aCardiovascular diseases:" exact="coronary artery disease" post="or congestive heart failure or vascular diseases. bCerebrovascular diseases:"/>
 <result pre="13 (7â€&quot;25) 6 (5â€&quot;12) 10 (6â€&quot;21) &amp;lt;0.001 aCardiovascular diseases: coronary" exact="artery disease" post="or congestive heart failure or vascular diseases. bCerebrovascular diseases:"/>
 <result pre="(7â€&quot;25) 6 (5â€&quot;12) 10 (6â€&quot;21) &amp;lt;0.001 aCardiovascular diseases: coronary artery" exact="disease" post="or congestive heart failure or vascular diseases. bCerebrovascular diseases:"/>
 <result pre="(5â€&quot;12) 10 (6â€&quot;21) &amp;lt;0.001 aCardiovascular diseases: coronary artery disease or" exact="congestive heart failure" post="or vascular diseases. bCerebrovascular diseases: stroke or transient ischemic"/>
 <result pre="10 (6â€&quot;21) &amp;lt;0.001 aCardiovascular diseases: coronary artery disease or congestive" exact="heart" post="failure or vascular diseases. bCerebrovascular diseases: stroke or transient"/>
 <result pre="aCardiovascular diseases: coronary artery disease or congestive heart failure or" exact="vascular" post="diseases. bCerebrovascular diseases: stroke or transient ischemic attack or"/>
 <result pre="disease or congestive heart failure or vascular diseases. bCerebrovascular diseases:" exact="stroke" post="or transient ischemic attack or hemiplegia. During hospitalisation, most"/>
 <result pre="congestive heart failure or vascular diseases. bCerebrovascular diseases: stroke or" exact="transient ischemic attack" post="or hemiplegia. During hospitalisation, most of the patients received"/>
 <result pre="heparin Â± lopinavir/r or darunavir/c or azithromycin (301, 55.8%). A" exact="total" post="of 117 patients (21.9%) required mechanical invasive (N ="/>
 <result pre="more frequently affected by comorbidities, suffered by a more severe" exact="disease" post="at presentation, and showed more frequently higher serum inflammatory"/>
 <result pre="comorbidities and Charlson index, inflammatory markers and d-dimer, severity of" exact="disease" post="and therapy combinations. A severe burden of comorbidity as"/>
 <result pre="&amp;gt;1000 ng/mL (AHR 1.67; 95% CI:1.12â€&quot;2.46), severe and critical COVID-19" exact="disease" post="at presentation (AHR: 1.77, 95%CI: 1.24â€&quot;2.53 and AHR 5.27,"/>
 <result pre="1.52 0.531 1.36 0.96 1.93 0.082 1.34 0.94 1.90 0.108" exact="Hypertension" post="(vs no) 1.72 1.27 2.33 &amp;lt;0.001 1.00 0.69 1.44"/>
 <result pre="(vs no) 1.72 1.27 2.33 &amp;lt;0.001 1.00 0.69 1.44 0.996" exact="Diabetes" post="(vs no) 1.71 1.22 2.40 0.002 1.32 0.89 1.95"/>
 <result pre="(vs no) 1.79 1.16 2.76 0.008 0.85 0.50 1.44 0.549" exact="Cancer" post="(vs no) 1.85 1.17 2.92 0.008 1.31 0.78 2.21"/>
 <result pre="(vs no) 1.85 1.17 2.92 0.008 1.31 0.78 2.21 0.304" exact="Chronic" post="obstructive pulmonary disease (vs no) 1.66 1.06 2.59 0.027"/>
 <result pre="1.85 1.17 2.92 0.008 1.31 0.78 2.21 0.304 Chronic obstructive" exact="pulmonary" post="disease (vs no) 1.66 1.06 2.59 0.027 1.25 0.77"/>
 <result pre="1.17 2.92 0.008 1.31 0.78 2.21 0.304 Chronic obstructive pulmonary" exact="disease" post="(vs no) 1.66 1.06 2.59 0.027 1.25 0.77 2.05"/>
 <result pre="(vs no) 1.66 1.06 2.59 0.027 1.25 0.77 2.05 0.369" exact="Chronic" post="liver diseases 0.97 0.45 2.07 0.935 Chronic kidney diseases"/>
 <result pre="0.77 2.05 0.369 Chronic liver diseases 0.97 0.45 2.07 0.935" exact="Chronic" post="kidney diseases 1.30 1.05 1.62 0.017 1.00 0.78 1.28"/>
 <result pre="2.05 0.369 Chronic liver diseases 0.97 0.45 2.07 0.935 Chronic" exact="kidney diseases" post="1.30 1.05 1.62 0.017 1.00 0.78 1.28 0.994 Obesiy"/>
 <result pre="1.06 2.32 0.023 Severity Â Mild/moderate 1.00 1.00 1.00 Â" exact="Severe" post="2.14 1.5 3.0 &amp;lt;0.001 1.77 1.24 2.53 0.002 1.76"/>
 <result pre="as statistically significant. aAdjsuted for all the factors showed. A" exact="total" post="of 55/117 (47.0%) patients who underwent mechanical ventilation died"/>
 <result pre="were associated with increased risk of death. In this setting" exact="obesity" post="was independently associated with a 2-fold higher risk of"/>
 <result pre="for not admission were age, presence of severe comorbidities and" exact="short" post="life expectancy. We then studied the dynamics of COVID-19"/>
 <result pre="the dynamics of COVID-19 disease, by investigating patients admitted and" exact="disease" post="severity in the 2-week time frames. We observed a"/>
 <result pre="the first peak most of the patients presented with severe" exact="disease" post="(55.4%) but only 13% were older than 79, during"/>
 <result pre="13% were older than 79, during the second peak the" exact="disease" post="was less frequently severe (35%) but more than half"/>
 <result pre="half of the patients (55%) were aged â‰¥80 and 30%" exact="acquired" post="the infection in long-term facilities residency (Table 3 )."/>
 <result pre="the patients (55%) were aged â‰¥80 and 30% acquired the" exact="infection" post="in long-term facilities residency (Table 3 ). Table 3"/>
 <result pre="(40.7) 67 (45.6) 42 (54.5) 20 (50.0) 14 (51.9) Â" exact="Severe" post="35 (50.7) 91 (51.4) 67 (45.6) 28 (36.4) 13"/>
 <result pre="In our study population of 539 patients hospitalised for COVID-19" exact="disease" post="we found an in-hospital mortality of 32%, reaching 44%"/>
 <result pre="32%, reaching 44% in patients undergoing mechanical ventilation. Patientsâ€™ age," exact="disease" post="severity at presentation, level of inflammation and concomitant comorbidities"/>
 <result pre="of high in-hospital mortality rate in our cohort are age," exact="disease" post="severity at admission and weight of comorbidities, as represented"/>
 <result pre="antivirals. The possible effectiveness and toxicity of hydroxychloroquine in Covid-19" exact="disease" post="is debated: laboratory studies showed antiviral properties (Devaux et"/>
 <result pre="et al., 2020). It should be considered that immune-mediated and" exact="vascular" post="mechanisms, and not only viral-related ones, might have a"/>
 <result pre="and not only viral-related ones, might have a role in" exact="disease" post="progression/death (Totura and Baric, 2012). Unfortunately, the low number"/>
 <result pre="in all studies on critically ill patients. In our setting" exact="obesity" post="was associated with death in critically ill patients who"/>
 <result pre="rate found in our setting could be related to the" exact="limited" post="number of beds in ICU, even if these were"/>
 <result pre="COVID-19 patients (Wunsch, 2020). A multidisciplinary equip of intensive care," exact="infectious diseases" post="and pneumology specialists, evaluated all the 67 patients with"/>
 <result pre="patients with P/F &amp;lt; 100 taking into account level of" exact="respiratory" post="distress, age, comorbidities and life expectancy. It is reasonable"/>
 <result pre="number of variables have not been adequately collected, in particularly" exact="obesity" post="(Simonnet et al., 2020), 50% of patients with unknown"/>
 <result pre="Second, we are not aware whether patients died for COVID-19" exact="disease" post="or with COVID-19 disease: actually, the association of risk"/>
 <result pre="a high rate of in-hospital death in patients with COVID-19" exact="disease" post="in a University hospital in Milan, the first European"/>
 <result pre="city to be overwhelmed by the epidemic of SARS CoV-2" exact="infection" post="in Europe. The severity of disease at presentation, the"/>
 <result pre="epidemic of SARS CoV-2 infection in Europe. The severity of" exact="disease" post="at presentation, the advanced age of patients, the level"/>
 <result pre="with severe Covid-19N Engl J Med38220201268127732109011 GuanW.NiZ.HuY.OuC.HeJ.LiuL.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med38220201708172032109013 GuaraldiG.MeschiariM.Cozzi-LepriA.MilicJ.TonelliR.MenozziM.Tocilizumab in patients"/>
 <result pre="COVID-19: a retrospective cohort studyLancet Rheumatol22020e474e48410.1016/52665-9913(20)30210-1[Published online 24 June]32835257 LennonH.SperrinM.BadrickE.RenehanA.G.The" exact="obesity" post="paradox in cancer: a reviewCurr Oncol Rep1820165627475805 LiuJ.CaoR.XuM.WangX.ZhangH.HuH.Hydroxycholoroquine, a"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov620201632194981 MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED: hydroxychloroquine or chloroquine with or"/>
 <result pre="PedersenS.F.HoY.C.SARS-CoV-2: a storm is ragingJ Clin Invest13020202202220532217834 SimonnetA.ChetbounM.PoissyJ.RaverdyV.NouletteJ.DuhamelA.High prevalence of" exact="obesity" post="in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive"/>
 <result pre="is ragingJ Clin Invest13020202202220532217834 SimonnetA.ChetbounM.PoissyJ.RaverdyV.NouletteJ.DuhamelA.High prevalence of obesity in severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilationObesity2820201195119932271993 Surveillance"/>
 <result pre="ragingJ Clin Invest13020202202220532217834 SimonnetA.ChetbounM.PoissyJ.RaverdyV.NouletteJ.DuhamelA.High prevalence of obesity in severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilationObesity2820201195119932271993 Surveillance of"/>
 <result pre="Clin Invest13020202202220532217834 SimonnetA.ChetbounM.PoissyJ.RaverdyV.NouletteJ.DuhamelA.High prevalence of obesity in severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilationObesity2820201195119932271993 Surveillance of COVID-19"/>
 <result pre="controlled trialBMJ3692020m184910.1136/bmj.m184932409561 ToturaA.L.BaricR.S.SARS coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferonCurr Opin Virol23201226427522572391 VenaA.GiacobbeD.R.Di BiagioA.MikulskaM.TaramassoL.De MariaA.Clinical characteristics,"/>
 <result pre="coronavirus (2019 nCoV) situation report-11Available at:2020https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19 WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="(2019 nCoV) situation report-11Available at:2020https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19 WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="situation report-11Available at:2020https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19 WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern Med1807202011110.1001/jamainternmed.2020.0994 WuZ.McGooganJ.M.Characteristics of"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern Med1807202011110.1001/jamainternmed.2020.0994 WuZ.McGooganJ.M.Characteristics of and important"/>
 <result pre="Intern Med1807202011110.1001/jamainternmed.2020.0994 WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID 19) outbreak in China. Summary of a"/>
 <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA32320201239124232091533 WunschH.Mechanical ventilation in COVID-19: interpreting the"/>
 <result pre="the current epidemiologyAm J Respir Crit Med2022020121 ZhiG.XinW.YingW.GuohongX.ShuyingL.â€œObesity paradoxâ€� in" exact="acute" post="respiratory distress syndrome: a systematic review and meta-analysisPLoS One1192016e0163677"/>
 <result pre="current epidemiologyAm J Respir Crit Med2022020121 ZhiG.XinW.YingW.GuohongX.ShuyingL.â€œObesity paradoxâ€� in acute" exact="respiratory" post="distress syndrome: a systematic review and meta-analysisPLoS One1192016e0163677 ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical"/>
 <result pre="meta-analysisPLoS One1192016e0163677 ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
</results>
